184368-70-5

Basic information

• Product Name: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected
• Synonyms: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected;trans-2,6-Dimethyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 184368-70-5
• Molecular Formula: C7H13NO
• Molecular Weight: 127.18422
• Mol File: 184368-70-5.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 308.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.027±0.06 g/cm3(Predicted)
• PKA: -1.46±0.60(Predicted)
• CAS DataBase Reference: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected(CAS DataBase Reference)
• NIST Chemistry Reference: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected(184368-70-5)
• EPA Substance Registry System: trans-2,6-Dimethylpiperidin-4-one,N-BOCprotected(184368-70-5)

Safety Data

• Hazardous Substances Data: 184368-70-5(Hazardous Substances Data)

Usage

Uses

(2R,6R)-Rel-2,6-dimethyl-4-oxo-1,1-dimethylethyl Ester 1-Piperidine Carboxylic Acid is a reagent in the preparation of some methylated analogs of isoguvacine derivatives which are potential GABAA agonists.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 13200-35-6 (2S,6R)-2,6-dimethylpiperidin-4-one 
• 32941-09-6 1-benzyl-2,6-dimethylpiperidin-4-one 
• 45717-87-1 2,6-dimethylpiperidin-4-one 
• 1005397-62-5 2,6-dimethylpiperidin-4-one hydrochloride 
• 198211-15-3 (2R,6S)-1-benzyl-2,6-dimethylpiperidin-4-one 
• 126503-08-0 N-Boc-7-methyl-1,4-dioxa-8-azaspiro<4.5>decane 
• 126503-27-3 trans-N-Boc-7,9-dimethyl-1,4-dioxa-8-azaspiro<4.5>decane 

Downstream Products

• 1005397-65-8 tert-butyl 2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 146337-39-5 tert-butyl (2S,6R)-4-hydroxy-2,6-dimethyl-piperidine-1-carboxylate 
• 146337-39-5 trans-N-Boc-2,6-dimethylpiperidin-4-ol 

Relevant articles and documents

4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

AMINOPYRIMIDINES AS ALK INHIBITORS

The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.

COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY

The present invention provides novel compounds of Formulas (I) and (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, or colorectal cancer), benign neoplasms, angio genesis, inflammatory diseases, fibrosis (e.g., polycystic kidney disease), autoinflammatory diseases, and autoimmune diseases in a subject.